Treatment of Cardiac Sarcoidosis

Treatment is tailored to the extent and activity of cardiac involvement, symptoms, heart rhythm and heart function. Decisions should be made by a cardiologist and a sarcoidosis specialist.

Immunosuppressive treatment

Corticosteroids are usually the first-line treatment when there is active myocardial inflammation, clinically important arrhythmia or impaired heart function. The dose is gradually reduced according to symptoms, imaging and laboratory results. Steroid-sparing medicines such as methotrexate, azathioprine or mycophenolate may be added when prolonged treatment is needed or side effects occur.

Treatment response is monitored with symptoms, ECG or Holter monitoring, echocardiography, cardiac MRI or FDG-PET, and blood tests such as troponin, BNP and inflammatory markers.

Treatment of rhythm disturbances

People with dangerous ventricular arrhythmias, significant conduction disease or a high risk of sudden cardiac death may need an implantable cardioverter-defibrillator (ICD). Pacemakers may be required for advanced heart block. Anti-arrhythmic medicines and catheter ablation are considered by the electrophysiology team when appropriate.

Heart failure care

Heart-failure treatment may include medicines that reduce the workload on the heart, diuretics for fluid retention and careful management of blood pressure. Severe cases may require specialised heart-failure services.

Follow-up

Cardiac sarcoidosis can relapse, so long-term follow-up is important even when symptoms improve. Seek urgent medical help for fainting, new chest pain, severe breathlessness or sustained palpitations. Never start, stop or change treatment without medical advice.

Nonsteroidal immunosuppressants may be an option for cardiac sarcoidosis

Treatment reduced corticosteroid requirements and lesion activity in some patients

A Japanese study suggests that nonsteroidal immunosuppressants may be a treatment option for people with cardiac sarcoidosis who do not respond well to corticosteroids or experience side effects from them.

Although these medicines reduced corticosteroid requirements and the activity of sarcoidosis lesions in some patients, further research is needed to establish their safety and effectiveness.

The study, “Cardiac sarcoidosis treated with nonsteroidal immunosuppressive therapy”, was published in IJC Heart & Vasculature.

The ILLUMINATE-CS registry used in the study was partly supported by a Novartis Pharma Research Grant. Novartis markets the nonsteroidal immunosuppressant cyclosporine under the names Sandimmune and Neoral.

Cardiac sarcoidosis occurs when granulomas, small clusters of inflammatory cells, affect the heart and interfere with its ability to pump blood around the body, potentially causing an irregular heartbeat and heart failure.

Corticosteroids do not work equally well for every patient. They can also cause serious side effects, such as weight gain and diabetes, particularly at high doses or with prolonged use.

Another treatment option for cardiac sarcoidosis?

The researchers used data from ILLUMINATE-CS (UMIN000034974), a registry of people with cardiac sarcoidosis in Japan.

According to the study abstract, the registry cohort comprised 512 patients, of whom 426 received corticosteroids and 26 received nonsteroidal immunosuppressants. Patients who received neither treatment or had missing data were excluded from the analysis.

Reasons for using nonsteroidal immunosuppressants included persistent heart inflammation, corticosteroid side effects, irregular heartbeats originating in the lower chambers of the heart and atrioventricular block, which can slow the heartbeat. Two patients had worsening sarcoidosis outside the heart.

Of the 26 patients receiving nonsteroidal immunosuppressants, 13 (50%) were men. The mean age at diagnosis was 60.3 years. The most common initial manifestations were impaired wall motion (42.3%), meaning changes in how well the heart muscle contracts, and atrioventricular block (34.6%), in which electrical signals normally travelling from the upper to the lower chambers of the heart are disrupted or blocked.

Methotrexate was the most frequently used nonsteroidal immunosuppressant, given to 20 patients. Three patients received azathioprine, two cyclosporine and two cyclophosphamide. In addition to reducing inflammation, methotrexate, azathioprine and cyclophosphamide also inhibit cell growth.

After nonsteroidal immunosuppressants were added to their treatment, 14 patients were able to reduce their corticosteroid doses, which may help reduce side effects. However, no patient stopped taking corticosteroids.

Among the 14 patients treated with nonsteroidal immunosuppressants because of persistent heart inflammation, half (50%) showed reduced fluorodeoxyglucose uptake on PET imaging. This reduction in uptake indicates reduced inflammation after treatment.

The researchers concluded that nonsteroidal immunosuppressive therapy may be an option for patients who are not stabilised with corticosteroids alone or who develop corticosteroid side effects. They noted that further research is needed to establish who might benefit most.

Source report: Sarcoidosis News

Original study: Cardiac sarcoidosis treated with nonsteroidal immunosuppressive therapy